LivaNova PLC (NASDAQ:LIVN) is named among the 12 best medical device stocks to invest in by Hedge Funds. Analyst Brett Fishbin at KeyBanc Capital Markets upgraded the stock rating to Overweight with a target price of $81, indicating a potential 27% upside.

The upgrade is part of KeyBanc’s positive outlook on the Medical Technology sector for 2026. The firm believes underlying trends are sustainable, and the segment’s valuation premium has decreased, making it an attractive stock picking scenario with increased capital markets activity.

Goldman Sachs analyst David Roman reaffirmed a Neutral rating on LivaNova PLC (NASDAQ:LIVN) with a price target increase to $66. He expects valuation to align with fundamentals in 2026 after significant divergence in the past year.

LivaNova PLC (NASDAQ:LIVN) develops and sells cardiovascular and neuromodulation solutions. Its cardiopulmonary segment offers various products, while the Neuromodulation segment provides VNS therapy systems and other neuromodulation devices.

While LIVN has investment potential, there are AI stocks with greater upside and less downside risk. For those interested in undervalued AI stocks benefiting from tariffs and onshoring, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: LivaNova (LIVN) Upgraded to Overweight by KeyBanc